Milestone PharmaceuticalsMIST
MIST
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
33% more capital invested
Capital invested by funds: $43.6M [Q3] → $57.9M (+$14.3M) [Q4]
7% more funds holding
Funds holding: 43 [Q3] → 46 (+3) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 14
7.79% less ownership
Funds ownership: 53.83% [Q3] → 46.04% (-7.79%) [Q4]
45% less call options, than puts
Call options by funds: $144K | Put options by funds: $264K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$25
1,011%
upside
Avg. target
$25
1,011%
upside
High target
$25
1,011%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 28% 1-year accuracy 51 / 180 met price target | 1,011%upside $25 | Buy Reiterated | 17 Mar 2025 |
Financial journalist opinion
Based on 5 articles about MIST published over the past 30 days
Positive
Seeking Alpha
6 days ago
Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers
In December 2023, Milestone Pharmaceuticals received an RTF letter from the FDA for insufficient TEAE data in their NDA filing, which precipitated a rapid decline in its share price. With an upcoming PDUFA in the PSVT indication, the company is approaching a binary event that will largely determine its future on the market. Considering Milestone's 2,000 patients worth of drug data across five clinical trials, we believe approval to be imminent for Etripamil and recommend a long position.
Neutral
GlobeNewsWire
1 week ago
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
MONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a moderated poster presentation at the American College of Cardiology annual meeting (ACC25), to be held March 29th to 31st, 2025 in Chicago, Illinois.
Neutral
GlobeNewsWire
2 weeks ago
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)
Neutral
GlobeNewsWire
3 weeks ago
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., March 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 94,000 options (the “Options”) to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the “Plan”), previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to employment of four new hires.
Neutral
GlobeNewsWire
4 weeks ago
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
MONTREAL and CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will present at the TD Cowen 45th Annual Health Care Conference, to take place from March 3-5, 2025 in Boston.
Neutral
GlobeNewsWire
1 month ago
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
MONTREAL and CHARLOTTE, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has received Notice of Allowance from the United States Patent and Trademark Office (USPTO) on a new Method of Use patent for etripamil nasal spray (proposed trade name CARDAMYST™), its lead investigational product for the management of paroxysmal supraventricular tachycardia (PSVT).
Neutral
GlobeNewsWire
1 month ago
Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025
MONTREAL and CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced further details on its in-person and virtual Commercial Launch Plan investor event to take place in New York on Tuesday, February 25, 2025 from 10:30 AM to 12:30 PM ET.
Neutral
GlobeNewsWire
1 month ago
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC
- PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)
Neutral
GlobeNewsWire
2 months ago
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 113,000 options (the “Options”) to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the “Plan”), previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to employment of three new hires.
Positive
Zacks Investment Research
4 months ago
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright
Milestone Pharmaceuticals Inc. (MIST) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MIST's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Charts implemented using Lightweight Charts™